Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28258060.
- Also identified by DOI 10.1158/1078-0432.CCR-16-2926 and PMC identifier 7372951.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Champiat and colleagues suggest that a small subset of patients at their center treated with PD1/PDL1 inhibitors appear to exhibit hyperprogression of disease. This commentary goes over some limitations in their preliminary analysis, a possible mechanism to explain the phenomenon, and a means by which other investigators can attempt to validate and further characterize these results. <i>Clin Cancer Res; 23(8); 1879-81. ©2017 AACR</i><i>See related article by Champiat et al., p. 1920</i>.
Medical subject headings
- Neoplasms